



May 9, 2017

## Corium to Report Preliminary Results from Corplex Donepezil Pilot Study and Second Quarter Fiscal 2017 Financial Results Before Market Open on Thursday, May 11, 2017

MENLO PARK, Calif., May 09, 2017 (GLOBE NEWSWIRE) -- Corium International, Inc. (NASDAQ:CORI) today announced that it will report preliminary results of the Corplex Donepezil pilot bioequivalence study as well as financial results for the second quarter ended March 31, 2017 on Thursday, May 11, 2017 before the open of the U.S. financial markets. Corium will host a conference call and live audio webcast at 8:30 a.m. Eastern time, 5:30 a.m. Pacific time to discuss its financial results and report on recent progress.

### Conference Call and Webcast Details

Investors and analysts can access the call toll-free by dialing (844) 831-3024 (United States) or +1 (315) 625-6887 (international). The conference ID# is 20268962. The conference call will also be available via a live audio webcast which may be accessed [here](#), or by visiting the Investors section of Corium's website at <http://ir.coriumgroup.com/events.cfm>. The webcast will be archived on the Corium website for two weeks following the presentation.

### About Corium

Corium International, Inc. is a commercial-stage biopharmaceutical company focused on the development, manufacture and commercialization of specialty pharmaceutical products that leverage the company's broad experience with advanced transdermal and transmucosal delivery systems. Corium has multiple proprietary programs in preclinical and clinical development, focusing primarily on the treatment of neurological disorders, with lead programs in Alzheimer's disease. Corium has developed and is the sole commercial manufacturer of seven prescription drug and consumer products with partners Mayne Pharma and Procter & Gamble. The company has two proprietary transdermal platforms: Corplex™ for small molecules and MicroCor®, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins. The company's late-stage pipeline includes a contraceptive patch co-developed with Agile Therapeutics and additional transdermal products that are being developed with other partners. For further information, please visit [www.coriumgroup.com](http://www.coriumgroup.com).

Corplex™ and MicroCor® are registered trademarks of Corium International, Inc.

Source: Corium

Investor and Media Contact:

SMP Communications

Susan Pietropaolo

[spietropaolo@bccpartners.com](mailto:spietropaolo@bccpartners.com)

(201) 923-2049

 Primary Logo

Source: Corium International, Inc.

News Provided by Acquire Media